Form 4: Imunon Director James E. Dentzer Acquires Stock Options

James E. Dentzer, a director of Imunon, Inc., was granted stock options to purchase 3,750 shares of common stock at an exercise price of $0.8651 on March 14, 2025.

Summary

• On March 14, 2025, James E. Dentzer, a director of Imunon, Inc., was granted stock options.
• The options allow Dentzer to purchase 3,750 shares of Imunon's common stock at an exercise price of $0.8651 per share.
• The options vest in three tranches: 1/2 on the grant date, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary of the grant date.
• Dentzer also signed a Power of Attorney, effective March 17, 2025, authorizing specific individuals to file SEC forms on his behalf.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock option grant) and doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This is a standard practice for incentivizing company directors and aligning their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their compensation packages for directors and executives.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates